Watch Ticker

Actuate Therapeutics, Inc. Common stock

Go to Actuate Therapeutics, Inc. Common stock Website

$7.31

0.00 (0.00%)

Live

Previous Close

$7.31

Day Range

$0 - $0

Previous Day Range

$6.8078 - $7.33

Market Cap

$144.7 million USD

Day Vol.

Previous Day Vol.

43614

Currency

USD

Primary Exchange

None

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglu...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics' Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival.

Related tickers: ACTU.

Read Full Article

N/A - Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate Therapeutics, a clinical-stage biopharmaceutical company, will present data on its investigational drug elraglusib for the treatment of advanced salivary gland carcinoma at the AACR Annual Meeting 2025. The data suggests elraglusib in combination with chemotherapy and immunotherapy may be a promising approach for this rare and difficult-to-treat cancer type.

Related tickers: ACTU.

Read Full Article

Trending Tickers

Please sign in to view